blog

Types of Dementia (It’s Not Just Alzheimer’s)

While Alzheimer's accounts for more than two-thirds of dementia cases, the ADDF also funds research to prevent and treat the other causes of dementia.

blog

Contact Sports & CTE: Are the Risks Too High?

A new study reveals a high percentage of former football players died with CTE, including 99% of NFL players tested.

announcements

$4 Million in New Grants Support Several First-in-Class Dementia Treatments

We recently awarded eight new grants totaling over $4 million to advance treatments for Alzheimer’s and related dementias. Several of the awards support new approaches to treating these diseases.

announcements

Experimental Imaging Agent Reveals Concussion-Linked Brain Disease in Living Brain

Protein tracer shows distinctive pattern of brain protein deposition specific to this disease and typically confirmed after death

announcements

Five New Grants Fund Promising Treatments & Biomarkers

The ADDF awarded five new grants in May and June 2016, totaling nearly $1.5 million.

announcements

Ten New Grants Support Alzheimer’s Drug Discovery and Biomarker Development

The ADDF has awarded 10 new grants to researchers developing drugs for neurodegenerative diseases and biomarkers to detect their onset and progression.

announcements

Asceneuron Awarded Alzheimer’s Drug Discovery Foundation Grant

Asceneuron SA, an emerging leader in small molecule therapeutics targeting tauopathies for Alzheimer's and related neurodegenerative diseases, was awarded a $325,000 grant from the ADDF to support the development of its tau modulators.

blog

New Drug Targets Are Highlight of Alzheimer’s Conference

Presenters at our recent conference shared exciting progress on new Alzheimer's drug targets and biomarkers. 

blog

5 Highlights from the Largest Alzheimer’s Conference

Our neuroscientists share highlights from their favorite sessions at the 2014 Alzheimer’s Association International Conference (AAIC) in Copenhagen, Denmark.